Clinical Trial: Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 1-2

U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT03283007) titled 'Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 1-2' on Sept. 6, 2017.

Brief Summary: Lung transplantation (TxP) is now a validated treatment of end-stage pulmonary diseases, but long-term graft and patient survival are still hampered by the development of chronic allograft dysfunction (CLAD) affecting > 50% of patients.

The investigators propose to conduct a phase III clinical randomized trial that will assess the efficacy of Nintedanib to hamper the lung decline in LTx recipients with BOS. This is the first trial testing this molecule in lung Tx recipients. If case of demonstrated effectivene...